The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The role of JAK inhibitors in treating MPNs and the need for disease-modifying agents
Elisabetta Abruzzese, MD, PhD, St Eugenio University Hospital, Rome, Italy, discusses the benefits and limitations of using JAK inhibitors to treat myeloproliferative neoplasms (MPNs), namely myelofibrosis (MF). Dr Abruzzese explains that while JAK inhibitors are effective at controlling symptoms such as splenomegaly, other disease-modifying agents may need to be identified to improve overall survival (OS) in patients with MPNs. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
